|
WO2021053690A1
|
|
An improved process for the preparation of baricitinib
|
|
WO2021009770A1
|
|
A process for the preparation of venetoclax and its polymorphs thereof
|
|
WO2020136671A1
|
|
Improved process for the preparation of lapatinib base and it's anhydrous ditosylate salt
|
|
WO2020121334A1
|
|
An improved process for the preparation of tipiracil hydrochloride and intermediates thereof
|
|
WO2020110146A1
|
|
Process for the preparation of high pure eribulin and its mesylate salt
|
|
WO2020105068A1
|
|
Process for the preparation of ecteinascidin derivative and its intermediate
|
|
WO2020058987A1
|
|
An improved process for the preparation of sugammadex sodium and its novel polymorphic form
|
|
WO2019234761A1
|
|
An improved process for the preparation of cabozantinib and its pharmaceutically acceptable salts thereof
|
|
WO2019207595A1
|
|
An improved process for the preparation of anthranilamide derivatives
|
|
WO2019180735A1
|
|
Stable pharmaceutical compositions comprising sacubitril-valsartan complex
|
|
WO2019171394A1
|
|
Stable pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride
|
|
WO2019155486A1
|
|
Process for the preparation of sorafenib tosylate polymorph iii
|
|
WO2019142207A1
|
|
Pharmaceutical compositions comprising ibrutinib
|
|
WO2019142206A1
|
|
An improved process for the preparation of ribociclib succinate and its novel crystalline forms thereof
|
|
WO2019138424A1
|
|
Stable pharmaceutical compositions comprising lenalidomide
|
|
US2020299248A1
|
|
Intermediates for the preparation of eribulin thereof
|
|
WO2019038779A1
|
|
A novel process for the preparation of an intermediate of alectinib
|
|
US2020095249A1
|
|
Process for the preparation of amorphous idelalisib
|
|
WO2019064310A1
|
|
An improved process for the preparation of elbasvir and its salt thereof
|
|
WO2018229785A1
|
|
Pharmaceutical compositions of ticagrelor
|
